Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In August 2017, the FDA approved tisagenlecleucel as the first CAR‑T therapy for patients up to 25 years old with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), including those who are refractory to treatment, in relapse after a transplant, or in their second or later relapse (1, 2).
In June 2018, the EMA granted marketing authorisation for Kymriah TM for children and young adults up to 25 years old with B-cell acute lymphoblastic leukemia (B-AL…